Post-COVID-19 syndrome, whose sufferers are known as “long-haulers,” is a chronic disease that BioSpace says “will likely define the first half of this decade.” Doctors are only just starting to think about therapies for the “long-haulers” disease, which causes symptoms as mild as fatigue to as serious as permanent lung damage. Doctors are saying that COVID-19 patients who do not start to feel better within two weeks are likely to be long-haulers. BioSpace has recently been in touch with several companies who are beginning to consider therapies for issues like lung fibrosis and respiratory problems. There are several clinical trials currently ongoing looking at the efficacy of different therapies on COVID-19 long-haul symptoms.